Compare Nasdaq Inc (NDAQ) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Repligen Corporation Common Stock — how do they compare? Nasdaq Inc trades at $92.34 (market cap $51.40B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Nasdaq Inc is far larger — about 4.5× Repligen Corporation Common Stock's market cap, and Nasdaq Inc pays a 1.26% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 126 Days and Repligen Corporation Common Stock for 0 Days on average.
| NDAQ | RGEN | |
|---|---|---|
Market Cap | $51.40B | $11.31B |
Volume | 3,601,938 | 1,216,919 |
Sector | Financials | Health |
52-Week High | $100.98 | $194.57 |
52-Week Low | $76.85 | $102.87 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | $57.86B | $11.20B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $93.48, down 0.86% on the day, with strong technical momentum showing a bullish moving average signal despite overbought RSI conditions. The company demonstrates robust fundamentals with 2025 revenue of $8.26B and net income of $1.79B, representing a 21.64% profit margin. Recent earnings beats and the launch of AI-powered Calypso platform highlight operational strength. Analyst consensus remains strongly bullish with a $110.43 price target, representing 18% upside potential from current levels.
NDAQ presents a compelling investment case with consistent earnings outperformance, strong profitability metrics, and strategic AI integration driving growth. However, elevated valuation multiples (P/E 27.25) and potential market volatility from exchange operations pose risks. The stock's technical positioning near resistance at $95 requires monitoring, but institutional support and positive analyst sentiment suggest continued upside potential for long-term investors.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
